It is also possible that RA-patients with high PCSK9 levels could be eligible for other types of therapy, or combinations with TNF-α-inhibition at an early stage, depending on whether other treatments, as established disease modifying anti-rheumatic drugs (DMARDs) or novel biological therapies are associated with baseline PCSK9-levels. The gene discussed is PCSK9; the disease is rheumatoid arthritis.